- Home
- CERS vs TBLA Comparison
CERS vs TBLA Comparison
Compare CERS & TBLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CERS | TBLA |
|---|---|---|
| Founded | 1991 | 2007 |
| Country | United States | United States |
| Employees | N/A | 2000 |
| Industry | EDP Services | Computer Software: Programming Data Processing |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.5M | 532.5M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CERS | TBLA |
|---|---|---|
| Price | $2.03 | $2.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $5.13 | ★ $5.88 |
| AVG Volume (30 Days) | ★ 2.0M | 1.7M |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.27 | ★ 1400.00 |
| EPS | N/A | ★ 280.00 |
| Revenue | $51,326,000.00 | ★ $1,912,040,000.00 |
| Revenue This Year | $17.63 | $1.65 |
| Revenue Next Year | $8.79 | $5.69 |
| P/E Ratio | ★ N/A | $0.01 |
| Revenue Growth | ★ 30.68 | 8.26 |
| 52 Week Low | $1.47 | $2.68 |
| 52 Week High | $3.47 | $5.71 |
Technical Indicators
Market Signals| Indicator | CERS | TBLA |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 14.05 |
| Support Level | $1.73 | N/A |
| Resistance Level | $2.15 | $3.53 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | -0.02 | -0.14 |
| Stochastic Oscillator | 1.55 | 1.59 |
Price Performance
Historical ComparisonAbout CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
About TBLA Taboola.com Ltd.
Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.